Printer Friendly

ZITHROMAX, FIRST ONCE-DAILY FIVE-DAY ORAL ANTIBIOTIC, APPROVED BY THE FOOD AND DRUG ADMINISTRATION

      ZITHROMAX, FIRST ONCE-DAILY FIVE-DAY ORAL ANTIBIOTIC, APPROVED
                   BY THE FOOD AND DRUG ADMINISTRATION
    NEW YORK, Nov. 4 /PRNewswire/ -- Pfizer Inc (NYSE: PFE) announced today that Zithromax(A) (azithromycin), the first azalide antibiotic for the treatment of community-acquired respiratory infections, skin infections and uncomplicated genital chlamydial infections, was approved by the U.S. Food and Drug Administration.
    The unique pharmacokinetic profile of Zithromax allows for effective, once-daily full-course oral antibiotic therapy in half the time required by conventional antibiotics.
    "Zithromax represents a breakthrough in convenience in oral antibiotic therapy," said William C. Steere Jr., president and chief executive officer of Pfizer Inc.  "We are very pleased to be able to bring this important new product to the many patients who will benefit from Zithromax."
    Zithromax is taken once-daily for only five days for respiratory tract and skin infections.  Most traditional therapies require 10 to 14 days of administration, usually with several daily doses.
    For uncomplicated chlamydial infections, a single 1-gram oral dose of Zithromax is required, instead of two to four times a day for seven days with other drugs.  This represents a breakthrough in therapy for this disease.
    Medical professionals generally agree that a shorter, simpler course of antibiotic therapy improves the likelihood that patients will complete the full course of treatment.
    Zithromax, the first azalide antibiotic, combines a unique pharmacokinetic profile with activity against a wide range of community- acquired infections and an excellent safety profile.  As with other antibiotics, the most common side effects are related to the gastrointestinal tract.
    Zithromax achieves high and sustained levels in tissue.  The tissue- penetrating ability of Zithromax distinguishes it from conventional agents and results in its significantly shortened dosing regimen.
    Pfizer Labs, a division of Pfizer Inc, will be responsible for marketing Zithromax.  Zithromax will be available shortly.
    Pfizer Inc is a diversified, research-based health care company with businesses in pharmaceuticals, hospital products, consumer products, animal health, and specialty chemicals and minerals.  The company reported sales of more than $6.4 billion for 1990.
    (A) -- Zithromax is a registered Pfizer trademark.
    -0-                        11/4/91
    /CONTACT:  A. A. Biesada, 212-573-2055, or Rick Honey, 212-573-2051, both of Pfizer/
    (PFE) CO:  Pfizer Inc ST:  New York IN:  MTC SU:  PDT GK-OS -- NY020 -- 0634 11/04/91 10:16 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1991
Words:376
Previous Article:APPLE COMPUTER DEMONSTRATES TECHNOLOGY SOLUTIONS AT CALS EXPO '91
Next Article:NATIONAL TECHTEAM ANNOUNCES EARNINGS FOR QUARTER ENDED SEPT. 30, 1991
Topics:


Related Articles
ZOLOFT, NEW PFIZER ANTIDEPRESSANT, GETS FDA APPROVAL; INTRODUCTION OF ZITHROMAX, NEW ANTIBIOTIC, DELAYED
PFIZER TO LAUNCH ZOLOFT AND ZITHROMAX; COMPANY TO INCREASE FOCUS ON HEALTH CARE; 1992 U.S. DRUG PRICE INCREASES NOT TO EXCEED 4 PERCENT
ZITHROMAX(R) (AZITHROMYCIN FOR ORAL SUSPENSION) APPROVED AS FIVE-DAY, ONCE-DAILY THERAPY FOR COMMON PEDIATRIC INFECTIONS
PFIZER RECEIVES CLEARANCE TO MARKET ZITHROMAX (AZITHROMYCIN) AS PREVENTION FOR A COMMON OPPORTUNISTIC INFECTION IN PERSONS WITH ADVANCED HIV INFECTION
Zithromax (Azithromycin) Significantly Reduces The Development Of Disseminated Mycobacterium Avium Complex (MAC) Disease In Persons With Advanced HIV...
Good News For Parents: The First and Only 5-Day, Once-Daily Children's Antibiotic Is Available for Common Pediatric Infections
Pfizer Completes First Large-Scale Study of Antibiotic Potential In Reducing Cardiovascular Events ---; WIZARD Trial Shows Short-Term Treatment With...
Pfizer's Zithromax Receives FDA Approval as a Once-Daily, Three-Day Treatment for Acute Bacterial Sinusitis.
Pfizer Launches Ophthalmics Products Group; Pfizer Committed to Maintaining 'Best-in-Class, First-in-Class' Leadership Position in Ophthalmology.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters